Guaifenesin warning letter
This article was originally published in The Tan Sheet
Executive Summary
Carolina Pharmaceuticals' guaifenesin- and potassium guaiacolsulfonate-containing products are unapproved new drugs, FDA states in a March 12 warning letter citing Humibid L.A. and Humibid DM (which also contains dextromethorphan). The agency "is unaware of substantial scientific evidence" showing such a combination "is generally recognized by qualified experts as safe and effective," the letter states. The products also are considered new drugs because labeling describes them as offering sustained-release formulations, which must be approved, FDA states. The letter notes the products are reformulated versions of drugs previously marketed under the Humibid brand. The Cary, N.C. firm purchased rights to the brand name at the end of a grace period temporarily allowing continued Rx sale of single-ingredient extended-release guaifenesin products (1"The Tan Sheet" March 3, 2003, p. 4)...
You may also be interested in...
FDA Focus On Food Safety Regulations May Delay OTC And Supplement Rules
FDA will try to eke out rules on OTC drug reviews and supplement labels in 2012 with its hands full implementing the food safety act. In the latest regulatory agenda, FDA priorities include an NPRM on foreign supplier verification and regulations to accredit third-party auditors to inspect firms across the agency’s oversight.
FDA Focus On Food Safety Regulations May Delay OTC And Supplement Rules
FDA will try to eke out rules on OTC drug reviews and supplement labels in 2012 with its hands full implementing the food safety act. In the latest regulatory agenda, FDA priorities include an NPRM on foreign supplier verification and regulations to accredit third-party auditors to inspect firms across the agency’s oversight.
Rx Extended-Release Guaifenesin Must Exit Market By November, FDA Says
Single-ingredient, extended-release prescription guaifenesin products must be removed from the market by the end of November if they have not been approved by FDA, the agency states in Feb. 25 letters to 66 marketers and distributors of the drugs